Cannabis And Heroin Are Not The Same And The DEA Is Coming To Terms With It: Event Unpacks What’s Next
In an unprecedented gathering of minds, the Benzinga Cannabis Capital Conference is set to highlight the brightest in the industry. Taking place on April 16-17 at The Diplomat Beach Resort, Hollywood, Florida, this event comes at a critical juncture as the cannabis industry anticipates a significant shift with potential rescheduling from Schedule I (a category it shares with drugs like heroin and LSD) to Schedule III (Tylenol with codeine, testosterone, etc.), opening new avenues for growth and innovation in the coming months.
“As we stand on the precipice of achieving long-fought cannabis reforms, convening leaders at the Benzinga Cannabis Capital Conference to discuss mutual challenges, objectives and opportunities could not come at a more critical time for our industry,” says Darren Weiss, president of Verano (OTC: VRNOF). “Unifying cannabis leaders together around common goals is crucial to ensuring we harness our collective power and influence to advocate for historic reforms that will finally unlock the full potential of America’s next great homegrown industry.”
Echoing Weiss’ sentiment, Matthew A. Karnes, founder of GreenWave Advisors, adds, “We are at an inflection point for federal reform, with the DEA likely approving cannabis reclassification to Schedule 3. This step is significant because it eliminates the punitive 280E tax burden and accelerates cash flow profiles for nearly all operators. The question then becomes: How will the cash savings be deployed? This year’s
Benzinga conference could answer …